Otsuka Corporation (OSUKF)

OTCMKTS · Delayed Price · Currency is USD
20.77
0.00 (0.00%)
Feb 10, 2026, 4:00 PM EST
Market Cap7.68B -6.9%
Revenue (ttm)8.44B +19.4%
Net Income410.13M +20.2%
EPS1.08 +19.9%
Shares Outn/a
PE Ratio18.73
Forward PEn/a
Dividend0.60 (2.89%)
Ex-Dividend DateDec 29, 2025
Volumen/a
Average Volume580
Open20.77
Previous Close20.77
Day's Range20.77 - 20.77
52-Week Range19.00 - 23.04
Beta0.30
RSIn/a
Earnings DateFeb 1, 2026

About Otsuka

Otsuka Corporation, together with its subsidiaries, operates as an information technology (IT) platformer in Japan. It operates through System Integration Business, and Service and Support Business segments. The System Integration Business segment offers management systems and collaborative software, such as ERP packages and groupware to cover a range of specialized fields, including CAD and web technologies; and software, hardware, intranet, and security products for the construction and expansion of computer networks, as well as intermediary ... [Read more]

Sector Technology
Founded 1961
Employees 9,680
Stock Exchange OTCMKTS
Ticker Symbol OSUKF
Full Company Profile

Financial Performance

In 2025, Otsuka's revenue was 1.32 trillion, an increase of 19.42% compared to the previous year's 1.11 trillion. Earnings were 64.30 billion, an increase of 20.24%.

Financial numbers in JPY Financial Statements

News

EU Approves DAWNZERA For Hereditary Angioedema, Says Ionis And Otsuka

(RTTNews) - Ionis Pharmaceuticals, Inc. (IONS) and Otsuka Pharmaceutical Co., Ltd. on Wednesday said the European Commission has approved Dawnzera to prevent repeated attacks of hereditary angioedema ...

21 days ago - Nasdaq

LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Otsuka Corp (4768)

LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Otsuka Corp (4768)

4 weeks ago - GuruFocus

4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop

4D Molecular Therapeutics centers on 4D-150 Wet-AMD Phase 3 timing, Otsuka funding to 2028, and mixed 4D-710 data with financial risk. See why FDMT stock is a hold.

7 weeks ago - Seeking Alpha

Otsuka Initiates Global Phase 3 Trial Of Repinatrabit For Phenylketonuria

(RTTNews) - Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced the launch of a global Phase 3 clinical trial for repinatrabit (JN...

7 weeks ago - Nasdaq

FDA Approves Otsuka's (OTSKF) Voyxact for IgAN Treatment

FDA Approves Otsuka's (OTSKF) Voyxact for IgAN Treatment

2 months ago - GuruFocus

Otsuka gains FDA approval for sibeprenlimab for proteinuria reduction

FDA approves Otsuka's Voyxact to reduce proteinuria in IgAN patients, showing a 51% drop in trials. Read more here.

2 months ago - Seeking Alpha

FDA Grants Accelerated Approval For Otsuka's VOYXACT In IgAN

(RTTNews) - Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval ...

2 months ago - Nasdaq